申请人:Bollag, Werner
公开号:EP1621191A1
公开(公告)日:2006-02-01
Retinoids with retinoid antagonistic activities, especially Retinoid X Receptor antagonists called RXR antagonists, pharmaceutically acceptable salts and pharmaceutically acceptable esters and amides thereof, have been found to be efficacious in the treatment of inflamatory diseases of the skin and mucous membranes, and of other tissues and organs especially by topical or oral administration of RXR antagonists.
研究发现,具有维甲酸拮抗活性的维甲酸类药物,尤其是被称为 RXR 拮抗剂的维甲酸 X 受体拮抗剂、其药学上可接受的盐类和药学上可接受的酯类和酰胺类药物,特别是通过局部或口服 RXR 拮抗剂,可有效治疗皮肤和粘膜以及其他组织和器官的炎症性疾病。